Table 3

Summary of the current study and previous studies on PGE1 therapy, as well as natural history studies on CRAO

NAge (years)Time from onsetBCVA (LogMAR)First visit1 month>3 monthsFeaturesComplicationType of ischaemia
Current2173.3±11.154.7±76.32.18±0.601.54±0.841.53±0.88Lipo-PGE1 10 µg intravenous/day×7–14 daysNothingNon-arteritic without cilioretinal artery sparing or transient with FA
Takai et al22669.3±15.18.3±3.4*2.57±0.18*1.62±0.86–†Free PGE1 80 µg intravenous/day×3–5 daysAngialgiaNon-arteritic without cilioretinal artery sparing through appearance
Kreutz et al211061.3±11.0*7.1±5.9*2.40±0.300.55±0.67*–†Free PGE1 80 µg intravenous/day×5 days+30 µg po/day×more than 1 monthAngialgia–†
Chen et al2717167.7±12.3>10.42.34±0.51–†2.24±0.63Natural history–†Non-arteritic without cilioretinal artery sparing or transient
  • Classical treatment: intraocular pressure-lowering agents (topical timolol 0.5%, oral methazolamide 50 mg), and vascular dilation agent (sublingual isosorbide dinitrate).

  • *Significantly different from the current study (p<0.05)

  • †Not listed.

  • BCVA, best-corrected visual acuity; CRAO, central retinal artery occlusion; FA, fluorescein angiography; lipo-PGE1, liposomal prostaglandin E1; LogMAR, logarithm of the minimal angle of resolution; po, per os.